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Summary of the article’s main point: 
Children and adolescents on tumor necrosis factor-alpha inhibitors are prone to severe 
tuberculosis disease, especially miliary tuberculosis, resulting in significant morbidity. False-
negative immunodiagnostic tests are common and a low threshold to initiate targeted 






In adults, anti-tumor-necrosis-factor (TNF)-α therapy is associated with progression of latent 
tuberculosis infection (LTBI) to tuberculosis (TB) disease. The existing paediatric data are very 
limited.  
Methods  
Retrospective multi-centre study within the Paediatric Tuberculosis Network European Trials 
Group, capturing patients <18 years who developed TB disease during anti-TNF-α therapy. 
Results  
Sixty-six tertiary healthcare institutions providing care for children with TB participated. 
Nineteen cases were identified; Crohn´s disease (n=8;42%) and juvenile idiopathic arthritis 
(n=6;32%) were the commonest underlying conditions. Immune-based TB screening (tuberculin 
skin test and/or interferon-gamma release assay) was performed in 15 patients before 
commencing anti-TNF-α therapy, but only identified one LTBI case; 13 patients were already 
receiving immunosuppressants at the time of screening. The median interval between starting 
anti-TNF-α therapy and TB diagnosis was 13.1 (IQR:7.1-20.3) months. All cases presented with 
severe disease, predominately miliary TB (n=14;78%). One case was diagnosed post-mortem. 
TB was microbiologically confirmed in 15 cases (79%). The median duration of anti-TB 
treatment was 50 (IQR:46-66) weeks. Five of 15 (33%) cases who had completed TB treatment 
had long-term sequelae. 
Conclusions  
The data indicate that LTBI screening is frequently false-negative in this patient population, 
likely due to immunosuppressants impairing test performance. Therefore, patients with 
immune-mediated diseases should be screened for LTBI at the point of diagnosis, before 
commencing immunosuppressive medication. Children on anti-TNF-α therapy are prone to 
severe TB disease, and significant long-term morbidity. Those observations underscore the need 




Etanercept was the first tumor necrosis factor-alpha (TNF)-α inhibitor to be approved for the 
treatment of juvenile idiopathic arthritis (JIA) in 1998, and the same year infliximab was 
approved for the treatment of Crohn’s disease. Several other anti-TNF-α agents have been 
approved since, which are increasingly being used to treat children affected by JIA, 
inflammatory bowel disease (IBD) and other immune-mediated conditions. In these patients, 
both the disease itself and the use of conventional immunosuppressant drugs and/or biologic 
agents are associated with an increased risk of serious infections, including tuberculosis (TB) 
[1-3]. 
 
In the human host immune response to mycobacterial infections TNF-α plays a critical role, 
particularly in the formation and maintenance of TB granulomas [4]. In adults, exposure to anti-
TNF-α agents has been associated with reactivation TB and progression from latent TB 
infection (LTBI) to TB disease, commonly manifesting as extrapulmonary or disseminated 
forms of TB [5]. Most current guidelines therefore emphasise the need to rule out LTBI before 
commencing anti-TNF-α therapy [6-8]. There is general consensus that patients who are 
diagnosed with LTBI based on a positive tuberculin skin test (TST) or interferon-gamma release 
assay (IGRA) result should receive anti-TB preventive therapy prior to commencing anti-TNF-α 
therapy. However, it currently remains uncertain if anti-TNF-α treatment has to be delayed until 
after the completion of preventive therapy, or whether it is safe to commence anti-TNF-α agents 
one or two months into preventive therapy. 
 
Currently the data on TB disease in children receiving anti-TNF-α therapy are very limited [9]. 
To our knowledge, fewer than 20 cases have been described in detail in the peer-reviewed 
literature so far [10-16]. Concerningly, several of those cases had a fatal outcome. 
 
Using a well-established network of paediatric specialists providing healthcare for children with 
TB, the aim of this study was to identify children and adolescents who developed TB disease 
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We conducted a retrospective multi-centre study within the Paediatric Tuberculosis Network 
European Trials Group (ptbnet) [17-20], a network of clinicians and researchers with an interest 
in paediatric TB, from September 2016 until March 2019. In March 2019 ptbnet comprised 252 
members based in 32 European countries and seven countries outside Europe, making it the 
largest paediatric TB network globally.  
 
Eligibility criteria and definitions 
All patients aged 0 to 18 years with confirmed TB disease (i.e. microbiologically proven by 
culture or nucleic acid amplification tests) and unconfirmed TB disease, based on the consensus 
case definitions proposed by Graham et al. [21], after initiation of anti-TNF-α therapy were 
eligible for inclusion. Severe TB disease was defined as per previously published criteria [22]. 
Significant hepatotoxicity was defined as serum aspartate aminotransferase or alanine 
aminotransferase concentrations >5 times the upper limit of normal (ULN) in asymptomatic 
patients, or >3 times the ULN in patients with symptoms (abdominal pain, nausea, vomiting or 
jaundice)[23]. 
 
Data collection and analyses 
A-standardised-data-collection-tool-(Online Supplementary Material [OSM] 1) was-
designed-and-all-ptbnet-members-were-invited-by-email-to-contribute-cases-to-this-study-in-
September-2016. The-data-collection-forms-received-were-collated-into-an-Excel-database 









Ethical approval for this study was obtained from the Hospital Sant Joan de Déu (Barcelona, 
Spain) Ethics Committee (reference PIC 133-13). No personal or identifiable data were 
collected during the conduct of this study. 
 
Results 
Collaborators from 66 tertiary and quaternary healthcare institutions providing care for children 
with TB participated in the study. Forty-nine (74%) centres reported that they had not 
encountered any patients fulfilling the case definitions during the preceding 5 years (OSM 2). A 
total of 19 patients (8 male;11 female) receiving anti-TNF-α therapy diagnosed with TB disease 
between February 2011 and March 2019 were identified. The largest numbers of cases were 
reported from Spain, Germany and the United Kingdom (each n=4). One case each was reported 
from healthcare centres in Austria, Croatia, Latvia, Lithuania, Portugal, Switzerland and 
Ukraine. Two of the cases (case 3 and case 4; Table 1) had previously been detailed elsewhere 
in case reports [10,11]. 
 
Characteristics of the cases identified 
The majority of the cases were Caucasian (n=15;79%) and born in the country where they were 
diagnosed (n=17;89%). Eleven (58%) cases had been BCG-vaccinated in the past; 8 (42%) were 
BCG-unvaccinated. The median age at diagnosis of the underlying inflammatory condition was 
9.7 (IQR: 6.6-12.8) years. The most common underlying conditions that prompted use of anti-
TNF-α therapy comprised Crohn´s disease (n=8;42%) and JIA (n=6;32%), as summarised in 
Table 1.  
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Risk factors for TB and screening for latent TB infection  
Almost half of the patients (n=9;47%) had risk factors for TB, including birth in, residence in or 
travel to a high TB prevalence country, residence in an urban area with high TB incidence 
and/or contact with an individual with TB disease before anti-TNF-α therapy was commenced. 
Screening for LTBI before starting anti-TNF-α therapy, either by TST or IGRA, was performed 
in 15 patients. Only one case had a positive TST result (case 4), and two had an indeterminate 
QFT-GIT result (cases 6 and 13). Two of these cases received a 9-month course of isoniazid 
prior to starting anti-TNF-α therapy (cases 4 and 13). Importantly, 13 (87%) of those 15 patients 
were receiving immunosuppressive therapy at the time when the TST and/or IGRA was 
performed. A chest x-ray was performed in 15 patients prior to commencing anti-TNF-α 
therapy; only one patient had abnormal radiological findings (case 11), comprising a calcified 
left supraclavicular lymph node without pulmonary changes.  
 
Clinical presentation of TB disease 
The median (IQR) age at diagnosis of TB disease was 14.3 (11.3-15.8) years. Eleven patients 
were receiving adalimumab, four infliximab and four etanercept at the time they were diagnosed 
with TB disease. The median (IQR) time interval between starting anti-TNF-α therapy and TB 
being diagnosed was 13.1 (7.1-20.3) months. Six (32%) patients (including four who had 
previously been screened for LTBI) had new risk factors for TB that occurred after commencing 
anti-TNF-α therapy, comprising recent contact with a TB disease case (n=4) and travel to a high 
TB prevalence country (n=2); in the remaining 13 (68%) patients no new risk factors were 
identified. In 6 (32%) of the patients, no risk factors for TB were identified either at initiation of 
anti-TNF-α therapy or subsequently. 
 
All patients presented with predefined severe disease, including miliary TB (n=14;74%), 
abdominal TB (n=8;42%), central nervous system TB (n=4;21%), pulmonary cavitation 
(n=4;21%), pericarditis (n=4;21%), osteoarticular TB (n=2;11%) and eye disease (n=1;5%). 
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Additional, non-severe disease manifestations comprised peripheral lymphadenitis (n=4;21%) 
and pleuritis (n=3;16%).  
 
The median (IQR) time interval between onset of symptoms and TB diagnosis was 3.3 (2.0-7.3) 
weeks. One patient was only diagnosed at a post-mortem examination (case 10). In 15 (79%) of 
the cases TB disease was microbiologically-confirmed by culture or nucleic acid amplification 
tests; the remaining 4 (21%) cases were diagnosed with TB disease based on symptoms and 
radiological findings consistent with TB.  
 
Of the non-confirmed cases, case 8 presented with fever and weight loss, and imaging revealed 
wide-spread miliary lesions in the lungs, liver and spleen; the initial IGRA result was 
indeterminate, but on re-testing the IGRA result converted to positive. Case 12 had intermittent 
fevers and weight loss, abnormal abdominal MRI findings and showed IGRA result conversion. 
Case 16 presented with fever and respiratory distress, and imaging revealed bilateral basal 
consolidation and right-sided pleural effusion; both TST and IGRA results were negative. Case 
19 presented with fever, cough, weight loss and diarrhoea, chest x-rays showed miliary changes 
and the IGRA result converted. All 4 patients responded to anti-TB treatment, with complete 
resolution of their constitutional symptoms.  
 
Performance of immune-based TB tests at presentation  
In 16 patients one or more immune-based TB test were performed when they presented with TB 
disease. A TST was performed in 6 patients; four had a positive, while two had a negative test 
result (case 4 already had a positive TST at baseline LTBI screening, but the induration 
diameter increased from 10 to 30 mm). A QFT assay was performed in 9 patients; 5 had a 
positive, two a negative and two an indeterminate test result. Only two patients had a T-
SPOT.TB assay performed; both were positive. Therefore, the test sensitivities of TST, QFT 
assays and T-SPOT.TB assays at presentation with TB disease were 66.7% (95%CI: 29.6-
90.1%), 55.6% (95%CI: 26.6-81.1%) and 100% (95%CI: 29.0-100%), respectively.     
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Treatment of TB disease 
One case was diagnosed post-mortem and never received anti-TB treatment (case 10). All 
remaining 18 patients were initially commenced on quadruple anti-TB treatment with 
rifampicin, isoniazid, pyrazinamide and ethambutol; one case was switched to another regimen 
after 3 days (case 17). The median (IQR) duration of anti-TB treatment was 50 (46-66) weeks. 
Although all isolated M. tuberculosis strains were susceptible to first-line oral anti-TB agents, 
second line drugs were used in 7 cases, either before the sensitivity pattern was known (due to 
concerns regarding possible drug-resistance), or because of toxicity with first line agents. Four 
patients experienced drug-induced adverse events related to anti-TB treatment, including 
significant hepatotoxicity (cases 4, 6 and 11), leukopenia (case 9), persistent blurred vision 
attributed to ethambutol (case 11), and hearing impairment that resolved after discontinuation of 
amikacin (case 6). Only one patient (case 4) underwent surgical intervention. 
 
Additional treatment 
Anti-TNF-α therapy was discontinued at TB diagnosis in all patients, except for one (case 15). 
Thirteen patients were commenced on corticosteroids, either as adjunctive treatment for TB 
disease and/or to treat flare-ups of their underlying immune-mediated disease. Five patients 
were commenced on other anti-inflammatory drugs to manage their underlying disease.  
 
Outcome 
Of the 18 patients who were alive at presentation, 10 (56%) were cured without long-term 
sequelae, 2 (11%) are still on anti-TB treatment with good clinical progress and 5 (28%) were 
cured but have significant long-term sequelae resulting from TB disease, including pulmonary 
fibrosis/cavitation (cases 2 and 7), persistent visual problems (case 11), restricted movement in 
the knee joint (case 4) and spinal instability (case 16). One case was lost to follow-up while still 
receiving treatment (case 18). Only in 4 patients anti-TNF-α treatment was subsequently 
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reintroduced after completion of TB treatment (cases 7, 12, 14 and 17), without any adverse 
events.    
 
Discussion 
To our knowledge, this is the largest study of TB disease associated with anti-TNF-α therapy in 
paediatric patients to date. The fact that only 19 cases were reported throughout our network 
indicates that TB disease may be a less common complication in children on anti-TNF-α 
therapy than in adults, considering the large number of specialist centres involved in this study.  
 
The relatively low number of TB cases may be the result of one or several of the following 
factors: a) lower incidence of LTBI in children compared with adults, b) low background TB 
prevalence in countries where anti-TNF-α agents are commonly used (which applies to all 
Northern, Western and Southern European countries), and c) successful implementation of 
LTBI screening prior to commencing anti-TNF-α therapy in the paediatric setting. Of the 32 
European countries where ptbnet members are based currently, only five are high TB 
prevalence countries – Lithuania (TB notifications in 2018: 49.9/100,000), Moldova 
(101.8/100,000), Romania (68.5/100,000), Russia (84.1/100,000), and Ukraine (76.7/100,000); 
the majority of the remaining 27 countries have TB incidences below 10.0/100,000 [24]. Given 
that anti-TNF-α agent use in children was uncommon for the first years after etanercept and 
infliximab had been approved, relatively few children would have received those drugs before 
the first report showing a strong association between anti-TNF-α agents and TB disease was 
published [25]. Following that report, routine LTBI screening prior to anti-TNF-α therapy, both 
in adults and in children, was incorporated into most national and international guidelines [6, 
26].  
 
Recent data from other studies further support the notion that TB disease is a relatively 
uncommon complication of anti-TNF-α therapy in children and adolescents in Europe. A multi-
centre study in Finland that included 348 patients with JIA, the majority of which were children 
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and adolescents at the time anti-TNF-α therapy was commenced, did not identify any cases of 
TB disease [27]. A German registry-based study that included 3350 paediatric patients with 
rheumatological conditions who received anti-TNF-α agents did also not identify any patients 
with TB disease [28]. Recently, a pharmacovigilance study that combined the data of 15,284 
JIA patients from different registries reported 14 cases of TB disease among children and 
adolescents receiving anti-TNF-α agents, although no details on disease manifestations were 
included [29]. Additional data kindly provided by the senior author (N. Ruperto; personal 
communication) revealed that only 12 of those cases had occurred in Europe, and that cases 
reported from the Russian Federation, where ptbnet currently only has one participating centre, 
accounted for the majority of those cases (n=7), providing further reassurance regarding the 
robustness of our data. 
 
Our study highlights the great severity of TB disease in children on anti-TNF-α therapy, 
consistent with previous case reports [10, 13-16]. All patients captured by our study presented 
with severe disease. Three quarters had miliary TB, which is associated with significant 
morbidity and mortality. This finding stands in stark contrast to TB disease in 
immunocompetent individuals, where miliary TB accounts for only about 2% of cases overall 
[30].  
 
Our study demonstrates the importance of routine LTBI screening in paediatric patients prior to 
commencing anti-TNF-α therapy, and simultaneously highlights the limitations of immune-
based LTBI screening in patients who are already receiving immunosuppressive therapy. Of the 
15 cases screened for LTBI among our cohort, only one had a positive test result. Of the 
remaining 14 patients, only 4 reported additional risk factors for acquiring TB after screening, 
comprising contact with an individual with TB disease and travel to a high TB prevalence 
country (n=3 and n=1, respectively). In those 4 patients de novo infection acquired after the 
screening procedure appears likely. Considering the absence of new risk factors after LTBI 
screening in the remaining 10 cases, reactivation of latent infection is the most likely underlying 
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mechanism. As most of those patients were receiving immunosuppressive treatment (other than 
anti-TNF-α agents) prior to LTBI screening, it is likely that their screening test results were 
false-negative, as both TSTs and IGRAs rely on the detection of intact anti-mycobacterial 
immune responses.  
 
Our data also highlight the suboptimal performance of TSTs and IGRAs as adjunctive tests in 
the diagnostic workup for suspected TB disease in patients on anti-TNF-α therapy. Although the 
number of test results available was relatively small, resulting in estimates with wide confidence 
intervals, the data indicate that only approximately half of those patients have a positive QFT 
assay result, a far lower proportion than previously reported in immunocompetent children [31]. 
This observation is in concordance with a recent study that showed that anti-TNF-α agents 
impair the performance of QFT assays substantially [32].   
 
It is well documented that the performance of TSTs is impaired in immunocompromised 
individuals, including patients with primary or secondary immunodeficiency and patients on 
immunosuppressive therapy [33]. Although some authors have stipulated that the performance 
of IGRAs is maintained in immunosuppressed individuals, recent data from in vitro studies 
show that a range of immunosuppressive agents - including corticosteroids, infliximab and 
calcineurin inhibitors - have a detrimental impact on IGRA performance, resulting in false-
negative test results in a substantial proportion of patients [32, 34, 35]. Therefore, as highlighted 
previously [36], we strongly believe that patients with immune-mediated inflammatory 
conditions should be screened for LTBI at the point when their diagnosis is established before 
commencing any immunosuppressive medication, as also suggested by a recent guideline [37]. 
Following initiation of immunosuppressive therapy, patients should be tested simultaneously 
with a TST and an IGRA to achieve greater sensitivity [36]. In this setting positive TST or 
IGRA test results remain useful for management decisions, but negative test results become 
uninterpretable, as it is currently impossible to determine whether a negative result in this 
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setting reflects absence of TB infection or alternatively a false-negative result caused by the 
inhibitory action of the immunosuppressive medication.    
 
Current guidelines do not recommend repeat LTBI screening at regular intervals, unless the 
patient develops symptoms consistent with TB or has new risk factors [7, 37]. Notably, nearly 
one third of the cases in our cohort had new risk factors after starting anti-TNF-α therapy, 
comprising known TB contact or overseas travel. Therefore, we believe that it is important to 
enquire about new TB risk factors at each patient contact during anti-TNF-α therapy. In patients 
who report a new risk factor, LTBI screening should be performed with a TST and an IGRA. If 
either test result is positive, LTBI treatment should be commenced once TB disease has been 
ruled out. In patients with concordantly negative results, clinicians should decide whether or not 
to start LTBI treatment based on a risk assessment (i.e. age of the patient, infectiousness of the 
index case, intensity of contact). 
 
Only four of the patients were recommenced on anti-TNF-α treatment after completion of active 
TB treatment; two continued on isoniazid as prophylaxis, while the remaining did not continue 
on any anti-TB drugs. None of these patients developed recurrence of TB. Given the limited 
published experience on re-introduction of anti-TNF-α agents after TB disease, it currently 
remains uncertain whether or not ‘secondary’ prophylaxis is warranted routinely. 
 
The main limitation of this study is its retrospective design, which can result in recall bias. 
However, it appears unlikely that any of the participating TB experts would not have recalled a 
patient who developed TB disease while receiving anti-TNF-α agents, as this is a well-known 
risk factor. Furthermore, our methodology does not allow us to estimate the incidence of TB 
disease in children receiving anti-TNF-α therapy as the denominator (i.e. number of children 
receiving anti-TNF-α therapy across all centres) is unknown. Additionally, we cannot exclude 
that further cases presented to other healthcare institutions that did not participate in this study. 
However, for many countries one or several leading national paediatric TB centres participated 
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in this study, and it appears unlikely that those centres would not have been contacted for advice 
if a case had occurred elsewhere in the country.  Finally, we can not exclude that there were 
additional cases with subclinical TB disease that were not diagnosed or cases who died before a 
diagnosis was established. 
 
In summary, our data indicate that TB disease may be less common in children and adolescents 
receiving anti-TNF-α therapy than in adults. However, the data show that children on anti-TNF-
α therapy who develop active TB are prone to severe TB disease, especially miliary TB. The 
disease severity and the short- and long-term morbidity observed in those patients underscores 
the need for robust LTBI screening programs in this high-risk patient population, even in low 
TB prevalence settings. Both patients receiving anti-TNF-α drugs and prescribing physicians 
need to be aware of the risks related to TB, and have a low threshold to initiate targeted 
investigations should a patient have new risk factors or develop symptoms compatible with TB 
disease. Additional, prospective research is needed to determine whether regular LTBI 
screening during anti-TNF-α therapy can help to further reduce the incidence of TB disease in 
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Details regarding TB disease  
and diagnostic tests at presentation 
Anti-TB and anti-
inflammatory drugs used,   
duration of treatment 
(weeks) 
TB outcome 
1 F, Caucasian, yes 
JIA,  
1.3 
No risk factors; TST 
3mm, negative QTF-





Miliary TB diagnosed after 9 days of fever, cough and anorexia. 
Positive QFT-GIT, sputum PCR-positive  
(cultures no growth) 
HRZE (14); HRZ (18) 
Steroids (12) for arthritis and 
uveitis flare; also MTX and 
ibuprofen 






2 F, Caucasian, yes 
Systemic JIA,  
3.0 
Born and living in high 
TB prevalence country; 
negative TST, normal 





Cavitary lesion in left upper lobe after 2 weeks of fever, fatigue, 
cough and anorexia; also developed left pleuritis, pericarditis and 
nodules in right lobe 4 weeks after initiation of anti-TB agents 
(probable immune reconstitution syndrome).   
TST 15mm, sputum culture- and PCR-positive (fully-susceptible 
MTB)  
HRZE+OFLO+AMIK (4); 
HRZE (8); HRE (36) 









Born and living in high 








Miliary TB with pleural & pericardial effusion and ascites diagnosed 
after 4 weeks of fever, cough, headache, joint pain, abdominal 
distention, and weight loss. 
Positive T-SPOT.TB, gastric aspirates culture- and PCR-positive 
(fully-susceptible MTB) 
HRZE (10); HRE (37) 
Steroids (10) for arthritis and 














TB contact; positive TST 
(10mm),  
normal CXR; 
on MTX and steroids. 






Miliary TB diagnosed after 2 weeks of fever, left inguinal 
lymphadenitis and arthritis in left knee;  
TST 30mm, synovial biopsy PCR-positive, gastric aspirates 
culture-positive  
(fully-susceptible MTB) 
HRZE (8); HR (18); 
treatment interruption due to 
significant hepatitis (4); HR 
(47) 
Also had knee synovectomy 
and inguinal lymph node 
excision,  
Steroids (8) for 





5 F, Caucasian, no 
JIA,  
7.2 
No risk factors; negative 
QFT-GIT, normal CXR, 
on MTX and steroids 
ETN (8.3) 
9.3, 
 TB contact 
Miliary TB, abdominal disease, cervical adenitis and erythema 
nodosum after 4 weeks of cough, anorexia and abdominal pain.  
Positive QFT-GIT, lymph node tissues culture- and PCR-positive 
(fully-susceptible MTB) 
HRZE (8); HR (41) 
Steroids (6) for miliary TB 
Cured without 
sequelae 
6 F, Caucasian, yes 
JIA,  
9.8 
Born in high TB 
prevalence country; 
indeterminate QFT-GIT, 




Miliary TB, inguinal lymphadenitis, abdominal disease, brain 
tuberculoma and spinal TB after 8 weeks of fever, weight loss and 
malaise. 
Indeterminate QFT-GIT, sputum culture- and PCR-positive (fully-
susceptible MTB) 
HRZE+AMIK+MOXI (9); 
HR+MOXI (41); Z stopped 
due to significant hepatitis; 
AMIK stopped due to 
hearing impairment  
Adherence issues 
Steroids for miliary TB 
Cured, spinal 
instability 
7 M, Caucasian, no 
Crohn´s 
disease, 8.8 
No risk factors; negative 




Cavitating lesion, airway compression and cervical lymphadenitis 
after 11 weeks of cough, anorexia and night sweats. 
Negative QFT-GIT, sputum culture- and PCR-positive (fully-
susceptible MTB) 
HRZE (12); HR (24) 
Steroids to treat airway 
compression and Crohn´s 
disease 
IFX reinitiated 7 months 






8 F, Asian, yes 
Crohn's 
disease, 9.7 
Family from and travel to 
high TB prevalence 
country; negative QFT-




trip to high TB 
prevalence 
country 
Miliary TB diagnosed after 3 weeks of fever, cough and weight 
loss. Chest x-ray and abdominal ultrasound showed miliary 
lesions.  
Indeterminate QFT-GIT initially (repeat after 8 weeks of anti-TB 
treatment positive),  
cultures no growth 




9 M, Caucasian, no 
Crohn's 
disease, 11.6 
No risk factors; no 
TST/IGRA done, normal 
CXR; 




trip to high TB 
prevalence 
country 
Miliary TB diagnosed after 4 weeks of fever, cough and weight 
loss. TST 10mm, sputum PCR-positive 
HRZE (13); HR, then 
H+RIFAB, then H+LEVO 






cutaneous TB at 
age 20.3 years 
(probable 
recurrence; no 
new risk factors) 
10 F, Caucasian, no 
Crohn's 
disease, 11.6 
Lived in an urban area 
with a TB incidence of 
70.0/100,000; negative 






4 weeks of fever and per-rectal bleeding; managed as flare of 
Crohn´s disease with immunosuppression and surgery, without 
improvement. Pulmonary haemorrhage and multiorgan failure; 
died after 3 weeks.  
Miliary TB was diagnosed post-mortem; liver, spleen and gut 
tissue PCR-positive  
TB treatment never initiated Died 
11 F, Asian, yes 
Crohn's 
disease, 13.0 
Family from and travel to 
high TB prevalence 
country, known TB 
contact; no TST/IGRA 
done, abnormal CXR; 




Cavitary pulmonary TB diagnosed after 1 week of fever, 
headaches, cough and night sweats. 
Positive T-SPOT.TB, sputum culture- and PCR-positive (fully-
susceptible MTB) 
HRZE (2), then 
HE+MOXI+AMIKA due to 
significant hepatitis (2); 
HE+MOXI (61); H+MOXI 









12 M, Asian, yes 
Crohn's 
disease, 13.6 
No risk factors; negative 
QFT-GIT, normal CXR;  




Abdominal TB diagnosed after 6 months of intermittent fever, 
abdominal pain, weight loss, vomiting and diarrhea. 
Positive QFT-GIT, cultures no growth 
HRZE (9); HR (20) 
No steroids 
Continued on H when IFX 




13 M, Caucasian, yes 
Crohn´s 
disease, 13.7 
No risk factors; 
indeterminate QFT-GIT, 
normal CXR; no 
immunosuppressive 
medication. 





Miliary TB with upper left lobe consolidation and splenic nodules 
after 2 weeks of fever, cough and pleuritic chest pain.  
Sputum culture- and PCR-positive (fully-susceptible MTB) 
HRZE+AMIK+LEVO (17); 
HR (35) Steroids (38) for 
persistent fever and Crohn´s 
flare  
Good clinical 
progress (still on 
TB treatment) 
14 








No risk factors; negative        
T-SPOT.TB, normal 





Lower left lobe and lingula consolidation with multiple parenchymal 
abscesses, pericarditis and splenic nodules after 16 weeks of 
gradually progressive dyspnoea, chest pain, cough, fever, weight 
loss and night sweats. 
Positive T-SPOT.TB, lung biopsy tissue PCR-positive   
HRZE+CLARITHRO+AMIK 
(3); HRE (18); HR (38) 
No steroids 
Continued on H when IFX 








Born and living in high 
TB prevalence country; 
no LTBI screening done 
(years earlier normal 
CXR and TST 10mm). 







Miliary TB, pleural and pericardial effusions after 3 weeks of fever, 
weight loss, worsening intestinal symptoms and cough.  
Streptomycin-resistant MTB in gastric aspirates 
HRZE+QUINOLONES (23); 
RZ (9); HR (14) 
Steroids and mesalazine for 
colitis flare 









Born in high TB 
prevalence country; 
negative QFT-GIT, 





Pleural TB diagnosed after one week of fever and respiratory 
distress (bilateral basal infiltrates).  
TST and QFT-GIT negative; sputum culture- and PCR-negative 
HRZE (8); HR (20) 
Steroids (6) for pleuritis; also 
tacrolimus and MMF 
Cured without 
sequelae 





No risk factors; no 







Miliary TB with abdominal and CNS involvement diagnosed after 8 
weeks of fever, cough, headaches, dizziness and weight loss.  
TST 12mm, positive QFT-GIT, sputum PCR- and culture-positive 
(fully-susceptible MTB) 
HRZE (3 days); HRZ+MOXI 
(16); HR (41) 
Steroids (8) for 
tuberculomas 
 ADA reinitiated 12 months 
after TB treatment 
completion 
 Cured without 
sequelae 




No risk factors; negative 
TST, normal CXR; 






Miliary TB diagnosed after 10 weeks of fever, cough and 
headaches. 
Negative TST, sputum culture-positive      
(fully-susceptible MTB), CSF culture- and  
PCR-negative 
HRZE (9); HR (poor 
adherence, intermittently 
126) 
Steroids (8) for meningeal 
and choroidal disease 
Lost to follow-up 
31 months after 
diagnosis 





No risk factors; negative 




Miliary TB after 5 weeks of fever, weight loss, cough and diarrhea. 
Positive QFT-GIT; gastric aspirates culture- and PCR-negative 
HRZE (4); HR (43) 
Steroids (33) 
Good clinical 
progress (still on 
TB treatment) 
ADA, adalimumab; AMIK, amikacin; AZA, azathioprine; CLARITHRO, clarithromycin; CNS, central nervous system; CXR, chest x-ray; ETN, etanercept; E, ethambutol; F, female; H, isoniazid; IGRA, 
interferon-gamma release assay; IFX, infliximab; JIA, juvenile idiopathic arthritis; LTBI, latent tuberculosis infection; LEVO,  levofloxacin; M, male; MOXI, moxifloxacin; MMF, mycophenolate mofetil; 
MTB, Mycobacterium tuberculosis; MTX, methotrexate; N/A, not applicable; NSAIDs, nonsteroidal anti-inflammatory drugs; OFLO, ofloxacin; PCR, polymerase chain reaction; QFT-GIT, QuantiFERON 
Gold-in-Tube (Cellestis/Qiagen; Carnegie, Australia); RIFAB, rifabutin; R, rifampicin; TB, tuberculosis; T-SPOT.TB (Oxford, Immunotec Ltd.; Oxford, UK); TST, tuberculin skin test; UCTD, 
undifferentiated connective tissue disease; Z, pyrazinamide 
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